Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

NCT01854216 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Rotigotine transdermal patch 1mg / 24 hours
DRUG: Rotigotine transdermal patch 2 mg / 24 hours
DRUG: Rotigotine transdermal patch 4 mg / 24 hours

Sponsor

UCB BIOSCIENCES GmbH